A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip

Phase 2

Not yet recruiting

• Conditions: Osteoarthritis of Hip
• Interventions: Drug: Zilretta; Drug: Triamcinolone Acetonide

• Registration Number: NCT06977568
• Lead Sponsor: Pacira Pharmaceuticals, Inc

Brief Summary

The goal of this clinical trial is to evaluate an injection procedure for the investigational drug in people with Osteoarthritis of the Hip. The Sponsor is conducting this research to evaluate successful injections in the hip by using two different needle sizes.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-07
• Study First Submitted QC: 2025-05-14
• Last Update Submitted: 2025-05-14
• Study First Posted: 2025-05-18
• Last Update Posted: 2025-05-18
• Study Start: 2025-06
• Primary Completion: 2025-12
• Study Completion: 2025-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• 1. Subjects must provide written informed consent prior to initiating any study specific procedures.

  2. Subjects must be willing and able to comply with the study procedures and visit schedule and to follow verbal and written instructions.

  3. Subjects must be male or female and 50 to 80 years old, inclusive, on the day of consent.

  4. Subjects must have a body mass index (BMI) ≤40 kg/m2 at Screening. 5. Subjects must exhibit symptoms associated with unilateral or bilateral hip OA for at least 6 months prior to Screening.

  5. Subjects with unilateral or bilateral hip pain must have an 24-hour average pain score (based on a numerical rating scale [NRS]) between ≥5.0 and ≤9.0 for the index hip and <5 in contralateral hip at Screening.

  6. Subjects must have K-L Grade 2 or 3 in the index hip (ie, the hip identified by the Investigator as appropriate for injection) confirmed by X ray obtained during Screening or within ≤6 months prior to the Screening visit.

  7. Subjects must have an index hip examination indicating the index hip and the intended injection site area are free of any signs of local or joint infection at Day 1/Baseline. Subjects must also not have a history of infection (eg, osteomyelitis) in the index hip or injection site.

  8. Sexually active subjects of child-bearing potential (SOCBP; defined as neither surgically sterile nor postmenopausal, ie, age >45 years and no menstrual periods for at least 1 year without an alternative medical cause) must agree to use, from Screening through 14 weeks postinjection for biologically female subjects and through 23 weeks postinjection for biologically male subjects, a highly effective method of contraception, defined as one of the following: abstinence; oral, injected, or implanted hormonal methods of contraception; intrauterine device or intrauterine contraceptive system; condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; or sexual intercourse only with biological male ≥6 months post-vasectomy.

Exclusion Criteria

• 1. Subjects who are pregnant, nursing, lactating, or plan to become, or their partner plans to become, pregnant during the study.

  2. Subjects with a history of hypersensitivity to triamcinolone acetonide, PLGA, or lidocaine.

  3. Subjects with hypersensitivity or allergy to Omnipaque 300 or iodine. 4. Subjects contraindicated to the use of acetaminophen/paracetamol (allowed rescue pain medicine) per National Product Labeling and Investigator's judgment.

  4. Subjects currently taking coumadin or have taken coumadin for ≥3 weeks prior to Day 1/Baseline.

  5. Subjects with a history of or active significant concomitant illness (known or suspected) including, but not limited to:

  • Inflammatory joint disease, eg, rheumatoid arthritis, seronegative spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory-bowel disease associated inflammatory arthritis.

  • Systemic inflammatory disease, eg, polymyalgia rheumatica, systemic lupus erythematosus.

  • Sarcoidosis or amyloidosis.

  • Cushing's syndrome.

  • Malignancy requiring systemic therapy within the past 5 years (excludes basal cell carcinoma or cervical cancer treated only with surgical removal more than 1 year prior).

  • Other autoimmune disease. 7. Subjects who have had any previous substantial hip injury (eg, hip dislocation, partial or complete hip fraction), which resulted in functional limitation or immobilization within 3 months prior to Screening.

    8. Subjects who have had prior surgery of the index hip either open or arthroscopic within 5 years of Screening.

    9. Subjects with any retained hardware or foreign body in the index hip. 10. Subjects with an index hip with major dysplasia or congenital abnormality, osteochondritis dissecans, acromegaly, ochronosis, hemochromatosis, Wilson's disease, primary osteochondromatosis, chondrolysis from a pain pump, or a history of avascular necrosis with secondary OA.

    10. Subjects with a diagnosis of other disorders in the index hip that can cause pain or any concurrent chronic joint, muscle, or nerve pain condition within 1 month prior to Screening (subject self-report acceptable), including but not limited to, back spine pain or conditions causing femoral nerve, obturator nerve, and sciatic nerve injury/entrapment; trochanteric bursitis; diabetic neuropathy of lower extremities; post-herpetic neuralgia; post-stroke pain; or fibromyalgia that may affect sensation of the index hip.

    11. Subjects who have used corticosteroids (any route of administration: IA intrabursal, intratendinous, intravenous [IV], intramuscular [IM], oral, intranasal, or inhaled) within 3 months of Screening except occasional (non-daily use <1 month) topical steroid use within 1 month prior to dosing. Treatment in another joint during this timeframe is exclusionary. Also, subjects who will require any steroid use while they are in the study are ineligible.

    12. Subjects who have received IA treatment in the index hip with any of the following agents within the 6 months or 5 half-lives prior to Screening: any biologic agent (eg, platelet rich plasma, stem cells, prolotherapy, amniotic fluid) or hyaluronic acid (investigational or marketed).

    13. Subjects with a history of or evidence of active or latent systemic fungal or mycobacterial infection (including tuberculosis), or of ocular herpes simplex.

    14. Subjects who have received a live vaccine (eg, measles, mumps, and rubella [MMR], varicella, influenza [nasal spray version only], Bacillus Calmette-Guérin [BCG], and polio) within 3 months prior to Screening.

    15. Subjects who have received an inactivated vaccination (eg, flu, COVID, tetanus, tetanus/diphtheria/pertussis [Tdap], hepatitis A) within 1 week prior to Screening and local injection pain has not resolved.

    16. Subjects with diabetes mellitus with hemoglobin A1c (HbA1c) >8.5% at Screening.

    17. Subjects with evidence of positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). Hepatitis B virus (HBV) immune subjects (ie, HBsAg-negative and hepatitis B antibody-positive) may, however, be included.

Note: Subjects who are negative for HBsAg, but positive for HBcAb, would be considered eligible if the absence of HBV DNA is confirmed by HBV DNA polymerase chain reaction reflex testing.

19. Subjects with chronic hepatitis C virus (HCV) (ie, positive HCV antibody [HCVAb] and HCV RNA).

Note: Subjects who are HCVAb-positive without evidence of HCV RNA may be considered eligible (spontaneous viral clearance or previously treated and cured [defined as no evidence of HCV RNA at least 3 months prior to Day 1/Baseline]).

20. Subjects with laboratory evidence of infection with human immunodeficiency virus (HIV).

21. Subjects who have any infection requiring parenteral antibiotics within 4 weeks of Day 1/Baseline or oral antibiotics within 2 weeks of Day 1/Baseline.

22. Subjects with active substance use disorder (drugs or alcohol) or history of substance use disorder within 12 months prior to Screening. Positive amphetamine results due to prescribed attention deficit/hyperactivity disorder (ADHD) medications with at least 6 months of stable dosing is permitted.

23. Subjects who use muscle relaxants (eg, cyclobenzaprine, tetrazepam, and diazepam) or oral/topical therapies (eg, nonsteroidal anti-inflammatory drugs [NSAIDs], cannabidiol [CBD] oil, capsaicin, lidocaine patches, or other local treatments) applied to the index hip within 1 month prior to Screening or within 5 half-lives of last dose.

24. Subjects who use selective serotonin reuptake inhibitors (SSRIs)/serotonin and norepinephrine reuptake inhibitors (SNRIs) (eg, fluoxetine, fluvoxamine, citalopram, escitalopram, sertraline, duloxetine, venlafaxine, and milnacipran) if the dose is not stable for at least 3 months prior to Screening. Subject must remain on a stable dose throughout the study.

25. Subjects using immunomodulators, immunosuppressives, or chemotherapeutic agents or have used any within 5 years of Screening.

26. Subjects using any other investigational drug, biologic, or device or have used any within 3 months of Screening.

27. Subjects who cannot washout prohibited medications (eg, opioids, other analgesics, and tetrahydrocannabinol [THC]- and CBD-containing products) or restricted medications.

28. Subjects who have any abnormal laboratory value(s) at Screening that, in the opinion of the Investigator (or other authorized clinical staff), precludes study participation.

29. Subjects with any other clinically significant acute or chronic pain condition that, in the judgment of the Investigator and in consultation with the Medical Monitor (MM) and/or sponsor, would or could compromise (or convey increased risk of) subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.

30. Subjects with any other clinically significant acute or chronic medical conditions (eg, autoimmune disorder; asthma/chronic obstructive pulmonary disease [COPD], or allergies requiring steroid use; bleeding disorder; other major hematological conditions, cardiac, renal, metabolic, gastrointestinal, neurologic, or psychiatric disease) that, in the judgment of the Investigator and/or in consultation with the MM, would preclude the use of the study drug or IA corticosteroids or that could compromise (or convey increased risk of) subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study.

31. Subjects are the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof directly involved in the conduct of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1A: ZILRETTA and 20G Needle	Zilretta	32mg ZILRETTA and 20-G Spinal Needle
1B ZILRETTA and 22G Needle	Zilretta	32mg ZILRETTA and 22-G Spinal Needle
2A TCA-IR and 20G Needle	Triamcinolone Acetonide	40mg TCA-IR and 20G Spinal Needle
2B TCA-IR and 22G Needle	Triamcinolone Acetonide	40mg TCA-IR and 22G Needle

Primary Outcome Measures

Name	Time	Method
Assessment of Successful Hip injection Rate	Day 1	The assessment of successful hip injection rate (injection of the full dose) for ZILRETTA and TCA-IR based on the 2 different needle-gauges

Secondary Outcome Measures

Name	Time	Method
Change in HOOS Survey	Change from Baseline to Week 1, Week 4, Week 8, and Week 12	Change from Baseline at Weeks 1, 4, 8, and 12 on the Hip Disability and Osteoarthritis Outcome Score (HOOS) total score and all subscales for ZILRETTA and TCA-IR. The HOOS includes 40 questions with five possible responses, graded from 0 to 4. Total HOOS to be calculated.
TEAE, AESIs, SAEs	From Day 1 through Week 12	Incidence of related treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and serious adverse events (SAEs) from Day 1 through Week 12 for ZILRETTA and TCA-IR.
Change in 24-hour average pain score	Change from Baseline to Week 1, Week 4, Week 8, and Week 12	Change from Baseline at Weeks 1, 4, 8, and 12 in the 24-hour average pain score (based on a numerical rating scale \[NRS\]) for ZILRETTA and TCA-IR . Average pain score is rated on a numerical scale between 0 (no pain) and 10 (worst possible pain).

Trial Locations

Locations (1)

Medical Pain Management Services PLLC; 🇺🇸 Albany, New York, United States